公开(公告)号：US20180200349A1

公开(公告)日：2018-07-19

申请号：US15893641

申请日：2018-02-11

Applicant: Atsuo Ochi

Inventor： Atsuo Ochi

IPC: A61K39/00 ,  A61K39/12 ,  A61K39/145 ,  A61K39/39 ,  C07K14/525 ,  C07K14/705 ,  C07K14/715

CPC classification number: A61K39/0008 ,  A61K38/177 ,  A61K38/1774 ,  A61K38/179 ,  A61K38/1793 ,  A61K39/12 ,  A61K39/145 ,  A61K39/39 ,  A61K2039/53 ,  A61K2039/55533 ,  A61K2039/6031 ,  A61K2039/70 ,  C07K14/525 ,  C07K14/705 ,  C07K14/70503 ,  C07K14/70532 ,  C07K14/7151 ,  C07K2319/30 ,  C12N5/00 ,  C12N15/09 ,  C12N2760/16134 ,  C12N2760/16234

Abstract: The invention relates to cell stimulatory fusion proteins and DNA sequences, vectors comprising at least two agonists of TNF/TNFR super family, immunoglobulin super family, cytokine family proteins and optional antigen combination. Instructions for use of these proteins and DNA constructs as immune adjuvants and vaccines for treatment of various chronic diseases such as viral infection are also provided. Additionally, the use of these protein and DNA constructs as immune suppressant for treatment of various chronic diseases, such as autoimmunity and organ transplant rejection, is also illustrated.

公开(公告)号：US10017576B2

公开(公告)日：2018-07-10

申请号：US15040375

申请日：2016-02-10

Applicant: Københavns Universitet ,  Cancer Research Technology Limited

Inventor： Henrik Clausen ,  Joy Burchell ,  Ulla Mandel ,  Anne Louise Sørensen ,  Mads Agervig Tarp ,  Joyce Taylor-Papadimitriou

IPC: C40B50/06 ,  C07K16/28 ,  A61K39/00 ,  C07K14/47 ,  C07K16/30 ,  G01N33/574 ,  G01N33/68 ,  A61K47/64 ,  C40B30/04

CPC classification number: C07K16/2896 ,  A61K39/0011 ,  A61K47/646 ,  A61K2039/5154 ,  A61K2039/5158 ,  A61K2039/6031 ,  A61K2039/6037 ,  A61K2039/6075 ,  A61K2039/6081 ,  C07K14/4727 ,  C07K16/28 ,  C07K16/30 ,  C07K16/3092 ,  C07K2317/14 ,  C07K2317/34 ,  C07K2317/76 ,  C40B30/04 ,  C40B50/06 ,  G01N33/574 ,  G01N33/6854 ,  Y02A50/412

Abstract: The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.

公开(公告)号：US20180177726A1

公开(公告)日：2018-06-28

申请号：US15897025

申请日：2018-02-14

Applicant: IMMUNOVACCINE TECHNOLOGIES, INC.

Inventor： Pirouz M. DAFTARIAN ,  Marc MANSOUR ,  Bill POHAJDAK ,  Robert G. BROWN ,  Wijbe M. KAST

IPC: A61K9/127 ,  C07K14/005 ,  A61K9/00 ,  A61K31/4745 ,  A61K39/00 ,  C12N9/90 ,  A61K39/12 ,  A61K39/385 ,  C07K14/47 ,  A61K47/64

CPC classification number: A61K9/127 ,  A01K2267/0331 ,  A61K9/0024 ,  A61K31/4745 ,  A61K39/00 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/385 ,  A61K47/646 ,  A61K2039/545 ,  A61K2039/55544 ,  A61K2039/55555 ,  A61K2039/55561 ,  A61K2039/55566 ,  A61K2039/585 ,  A61K2039/6031 ,  A61K2039/6037 ,  A61K2039/622 ,  A61K2039/627 ,  A61K2039/70 ,  C07K14/005 ,  C07K14/4748 ,  C07K2319/00 ,  C12N9/90 ,  C12N2710/20022 ,  C12N2710/20034 ,  C12Y503/03012

Abstract: The invention compositions comprising a continuous hydrophobic phase and liposomes as a vehicle for delivery of an antigen capable of inducing a cytotoxic T lymphocyte (CTL) response and methods for their use in the treatment of cancer.

公开(公告)号：US20180169208A1

公开(公告)日：2018-06-21

申请号：US15886112

申请日：2018-02-01

Applicant: Wichita State University ,  Case Western Reserve University

Inventor： James G. Bann ,  Masaru Miyagi

IPC: A61K39/07 ,  A61K45/06 ,  A61K39/40 ,  A61K39/00

CPC classification number: A61K39/07 ,  A61K39/40 ,  A61K45/06 ,  A61K2039/6031 ,  A61K2039/622

Abstract: Immunogenic compositions against Bacillus anthracis comprising a stabilized protective antigen complex are disclosed. The stabilized complex comprises protective antigen protein and capillary morphogenesis protein-2, with the capillary morphogenesis protein-2 being bound to the protective antigen protein along a binding interface. The stabilized protective antigen complex has increased thermal and structural stability, along with resistance to premature proteolytic degradation. Methods of using the same to induce an immunogenic response in a subject against B. anthracis infection are also disclosed.

公开(公告)号：US20180133339A1

公开(公告)日：2018-05-17

申请号：US15557651

申请日：2016-03-16

Applicant: Amal Therapeutics SA

Inventor： Madiha DEROUAZI ,  Elodie BELNOUE

IPC: A61K47/68 ,  A61K39/00 ,  A61P35/00 ,  A61K47/64

CPC classification number: A61K47/42 ,  A61K38/10 ,  A61K38/17 ,  A61K38/1764 ,  A61K38/177 ,  A61K39/0011 ,  A61K47/64 ,  A61K47/6425 ,  A61K47/6803 ,  A61K47/6811 ,  A61K47/6865 ,  A61K2039/5154 ,  A61K2039/6031 ,  A61P1/00 ,  A61P35/00 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/10 ,  C07K2319/33 ,  C07K2319/40 ,  C12N2710/16233 ,  Y02A50/41 ,  Y02A50/469

Abstract: The present invention provides a novel complex for use in the prevention and/or treatment of glioma, in particular glioblastoma, the complex comprising a) a cell penetrating peptide, b) at least one antigen or antigenic epitope, and c) at least one TLR peptide agonist, wherein the components a)-c) are covalently linked. In particular, compositions for use in the prevention and/or treatment of glioma, in particular glioblastoma, such as a pharmaceutical compositions and vaccines are provided.

公开(公告)号：US20180100011A1

公开(公告)日：2018-04-12

申请号：US15820310

申请日：2017-11-21

Applicant: École Polytechnique Fédérale de Lausanne (EPFL)

Inventor： Jeffrey A. Hubbell ,  Stephan Kontos ,  Karen Y. Dane

IPC: C07K16/18 ,  C12N9/82 ,  A61K39/00 ,  C07K7/08 ,  C07K14/62 ,  C07K14/74 ,  C07K16/28 ,  A61K9/51 ,  A61K9/107 ,  A61K38/00

CPC classification number: C07K16/18 ,  A61K9/1075 ,  A61K9/513 ,  A61K38/00 ,  A61K39/0008 ,  A61K39/001 ,  A61K47/60 ,  A61K47/62 ,  A61K47/64 ,  A61K47/646 ,  A61K47/6811 ,  A61K47/6849 ,  A61K47/6901 ,  A61K2039/505 ,  A61K2039/6031 ,  A61K2039/6056 ,  A61K2039/627 ,  C07K7/08 ,  C07K14/62 ,  C07K14/70539 ,  C07K16/2896 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2317/92 ,  C07K2319/00 ,  C07K2319/21 ,  C07K2319/22 ,  C07K2319/23 ,  C07K2319/33 ,  C07K2319/41 ,  C07K2319/43 ,  C07K2319/74 ,  C12N9/82 ,  C12Y305/01001

Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.

公开(公告)号：US09932372B2

公开(公告)日：2018-04-03

申请号：US13808974

申请日：2010-07-08

Applicant: Chang Yi Wang ,  Wen-Jiun Peng

Inventor： Chang Yi Wang ,  Wen-Jiun Peng

IPC: C07K14/01 ,  A61K39/12 ,  G01N33/68 ,  A61K39/00

CPC classification number: C07K14/01 ,  A61K39/12 ,  A61K2039/552 ,  A61K2039/55566 ,  A61K2039/6031 ,  C12N2710/24111 ,  C12N2710/24143 ,  C12N2770/32011 ,  C12N2770/32034 ,  G01N33/6878

Abstract: Porcine circovirus (PCV2) vaccine compositions comprising a peptide antigen derived from a PCV2 capsid protein are described. In various embodiments, the peptide antigen contains amino acids of the capsid protein from about amino acid 47 to about amino acid 202. In some embodiments, the peptide antigen is optionally linked to an artificial T helper epitope and/or mixed with T helper epitopes derived from the ORF1 and ORF3 proteins of PCV2. Methods of using PCV2 vaccine compositions are also described. In various embodiments, a vaccine composition is used in animals for the prevention of PCV2 infection. In other embodiments, a PCV2 vaccine composition is used as an antigen for diagnosing PCV2 infection.

公开(公告)号：US09931385B2

公开(公告)日：2018-04-03

申请号：US14383564

申请日：2013-03-11

Applicant: University of Nordland

Inventor： Igor Babiak ,  Reid Hole

IPC: A61K39/00 ,  A61K47/64

CPC classification number: A61K39/0005 ,  A61K47/646 ,  A61K2039/552 ,  A61K2039/6031

Abstract: The present invention provides a method of inhibiting maturation of the gonads of a juvenile animal which comprises administering to said juvenile animal an immunologically active molecule (IAM) or a vector comprising nucleic acid encoding an immunologically active molecule, said IAM being specific for a target protein within the gonads and binding thereto or causing an immune response against that target protein, and thereby inhibiting maturation of the gonads, as well as molecules of use in such methods.

公开(公告)号：US09901632B2

公开(公告)日：2018-02-27

申请号：US14436239

申请日：2013-10-21

Applicant: The Council of the Queensland Institute of Medical Research

Inventor： Rajiv Khanna ,  Dasari Vijayendra

IPC: A61K39/245 ,  C12N7/00 ,  C07K14/005 ,  C12N5/0783 ,  A61K39/00

CPC classification number: A61K39/245 ,  A61K2039/572 ,  A61K2039/6031 ,  A61K2039/70 ,  C07K14/005 ,  C07K2319/00 ,  C07K2319/21 ,  C07K2319/40 ,  C12N5/0638 ,  C12N7/00 ,  C12N2501/998 ,  C12N2710/16122 ,  C12N2710/16134 ,  C12N2710/16222 ,  C12N2710/16234

Abstract: An isolated protein comprises respective amino acid sequences of each of a plurality of CTL epitopes from two or more different herpesvirus antigens and further comprises an intervening amino acid or amino acid sequence between at least two of said CTL epitopes comprising proteasome liberation amino acids or amino acid sequences and, optionally, Transporter Associated with Antigen Processing recognition motifs. The isolated protein is capable of rapidly expanding human cytotoxic T lymphocytes (CTL) in vitro and eliciting a CTL immune response in vivo upon administration to an animal as an exogenous protein. Typically, the isolated protein comprises no more than twenty (20) CTL epitopes derived from cytomegalovirus and/or Epstein-Barr virus antigens.

公开(公告)号：US09861690B2

公开(公告)日：2018-01-09

申请号：US15174643

申请日：2016-06-06

Applicant: The Ohio State University Research Foundation

Inventor： Yasuko Rikihisa

IPC: A61K39/02 ,  A61K38/04 ,  G01N33/53 ,  C07K14/29 ,  C07K7/08 ,  G01N33/569 ,  G01N33/68 ,  A61K38/00 ,  A61K39/00

CPC classification number: A61K39/0233 ,  A61K38/00 ,  A61K38/04 ,  A61K2039/552 ,  A61K2039/575 ,  A61K2039/6031 ,  C07K7/08 ,  C07K14/29 ,  G01N33/53 ,  G01N33/56911 ,  G01N33/6854 ,  G01N2333/29 ,  G01N2469/20 ,  Y02A50/402

Abstract: The novel omp-1 gene cluster encoding twenty one Ehrlichia ewingii (EE) proteins was isolated and sequenced completely. This invention relates to isolated E. ewinigii (EE) polypeptides, isolated polynucleotides encoding EE polypeptides, probes, primers, isolated antibodies and methods of their production, immunogenic compositions and vaccines, as well as methods of using the EE polypeptides, antibodies, probes, and primers for the purpose of diagnosis, therapy and production of vaccines against E. ewingii.